Summit Therapeutics PLC (NASDAQ:SMMT) has been given an average rating of “Buy” by the seven analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $25.00.

SMMT has been the topic of several recent research reports. Zacks Investment Research upgraded Summit Therapeutics PLC from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Tuesday, July 4th. Oppenheimer Holdings, Inc. set a $24.00 price objective on Summit Therapeutics PLC and gave the company a “buy” rating in a report on Thursday, June 22nd. Canaccord Genuity reiterated a “buy” rating and issued a $28.00 price objective on shares of Summit Therapeutics PLC in a report on Friday, June 16th. Finally, ValuEngine upgraded Summit Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Tuesday, June 6th.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/08/summit-therapeutics-plc-nasdaqsmmt-receives-average-rating-of-buy-from-analysts.html.

An institutional investor recently bought a new position in Summit Therapeutics PLC stock. Acadian Asset Management LLC bought a new position in shares of Summit Therapeutics PLC (NASDAQ:SMMT) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 12,850 shares of the company’s stock, valued at approximately $171,000. Acadian Asset Management LLC owned about 0.10% of Summit Therapeutics PLC at the end of the most recent reporting period. Institutional investors own 21.86% of the company’s stock.

Summit Therapeutics PLC (NASDAQ SMMT) traded up 0.21% during trading on Tuesday, reaching $14.50. The company’s stock had a trading volume of 2,139 shares. The stock has a 50 day moving average price of $11.98 and a 200 day moving average price of $11.71. Summit Therapeutics PLC has a 1-year low of $5.31 and a 1-year high of $19.75. The stock’s market capitalization is $179.52 million.

Summit Therapeutics PLC Company Profile

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Analyst Recommendations for Summit Therapeutics PLC (NASDAQ:SMMT)

Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.